Literature DB >> 22614208

Ipilimumab-induced colitis on FDG PET/CT.

Ashima Lyall1, Herbert Alberto Vargas, Richard D Carvajal, Gary Ulaner.   

Abstract

A 52-year-old woman with metastatic melanoma was treated with ipilimumab. After 2 cycles of treatment, she developed watery diarrhea, sweats, and chills. An FDG PET/CT study demonstrated new FDG-avid (maximum standardized uptake value 15.6) diffuse colonic wall thickening, suggestive of ipilimumab-induced colitis. The patient was treated with systemic steroids, with subsequent resolution of her symptoms. Based on the response to steroids, the diagnosis of ipilimumab-induced enterocolitis was made. Ipilimumab may cause several immune-mediated toxicities, the most common of which is enterocolitis. Physicians interpreting FDG PET/CT examinations of patients treated with ipilimumab should be aware of these FDG-avid immune-mediated toxicities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614208     DOI: 10.1097/RLU.0b013e318248549a

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

Review 1.  Gastrointestinal adverse events of immunotherapy.

Authors:  Giovanni Cappello; Francesca Molea; Delia Campanella; Francesca Galioto; Filippo Russo; Daniele Regge
Journal:  BJR Open       Date:  2021-10-20

2.  Ipilimumab associated hepatitis: imaging and clinicopathologic findings.

Authors:  Kyung Won Kim; Nikhil H Ramaiya; Katherine M Krajewski; Jyothi P Jagannathan; Sree Harsha Tirumani; Amitabh Srivastava; Nageatte Ibrahim
Journal:  Invest New Drugs       Date:  2013-02-14       Impact factor: 3.850

3.  [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].

Authors:  J K Tietze; M Heppt; D Angelova; T Ruzicka; F Berger; C Berking
Journal:  Hautarzt       Date:  2017-08       Impact factor: 0.751

Review 4.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.

Authors:  Stefano Frega; Alessandro Dal Maso; Giulia Pasello; Lea Cuppari; Laura Bonanno; PierFranco Conte; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

5.  Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.

Authors:  E Lopci; R J Hicks; A Dimitrakopoulou-Strauss; L Dercle; A Iravani; R D Seban; C Sachpekidis; O Humbert; O Gheysens; A W J M Glaudemans; W Weber; R L Wahl; A M Scott; N Pandit-Taskar; N Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-04       Impact factor: 10.057

Review 6.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.